These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23541771)

  • 1. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.
    Baldewpersad Tewarie NM; Burgers IA; Dawood Y; den Boon HC; den Brok MG; Klunder JH; Koopmans KB; Rademaker E; van den Broek HB; van den Bersselaar SM; Witjes JJ; Van Noorden CJ; Atai NA
    Med Hypotheses; 2013 Jun; 80(6):728-31. PubMed ID: 23541771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
    Bleeker FE; Atai NA; Lamba S; Jonker A; Rijkeboer D; Bosch KS; Tigchelaar W; Troost D; Vandertop WP; Bardelli A; Van Noorden CJ
    Acta Neuropathol; 2010 Apr; 119(4):487-94. PubMed ID: 20127344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
    Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
    Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Chamberlain MC
    Neurology; 2014 Jun; 82(23):2147-8. PubMed ID: 24912510
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
    van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
    Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
    Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
    Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic markers in gliomas - an update.
    Ma R; de Pennington N; Hofer M; Blesing C; Stacey R
    Br J Neurosurg; 2013 Jun; 27(3):311-5. PubMed ID: 23278177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
    Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
    Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
    Fu Y; Huang R; Zheng Y; Zhang Z; Liang A
    Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic markers in gliomas.
    Labussiere M; Wang XW; Idbaih A; Ducray F; Sanson M
    Future Oncol; 2010 May; 6(5):733-9. PubMed ID: 20465388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of
    Yaltirik CK; Yilmaz SG; Ozdogan S; Bilgin EY; Barut Z; Ture U; Isbir T
    In Vivo; 2022; 36(4):1694-1702. PubMed ID: 35738587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.